TABLE OF CONTENTS
Volume 81, Issue 1 (January 2007)
Editorial |
News and Views |
Perspectives |
State of the Art |
Research |
Discovery & Development |
Regulation & Use
Contents
In this issue
Clin Pharmacol Ther 81: 1; doi:10.1038/sj.clpt.6100031
See also: Macroscopy by RidingerSee also: State of the Art by PangSee also: Article by Chen et al. See also: Discovery by Zingman et al. See also: Ethics by LeeSee also: Public Policy by ZerhouniEditorial
Editorial
Clinical pharmacology: the science of therapeutics
S A Waldman, N B Christensen, J E Moore and A Terzic
Clin Pharmacol Ther 81: 3-6; doi:10.1038/sj.clpt.6100032
News and Views
Highlights
Highlights
Carrie Nathans
Clin Pharmacol Ther 81: 8-9; doi:10.1038/sj.clpt.6100057
ASCPT News
ASCPT News
Clin Pharmacol Ther 81: 10-11; doi:10.1038/sj.clpt.6100026
Macroscopy
The electronic prescription conundrum: Why "e-Rx" isn't so "e-Z"
M H T Ridinger
Clin Pharmacol Ther 81: 13-15; doi:10.1038/sj.clpt.6100022
Perspectives
Point-Counterpoint
The value and future of clinical pharmacology
P Honig
Clin Pharmacol Ther 81: 17-18; doi:10.1038/sj.clpt.6100024
Clinical pharmacology or translational medicine and therapeutics: reinvent or rebrand and expand?
G A FitzGerald
Clin Pharmacol Ther 81: 19-20; doi:10.1038/sj.clpt.6100044
Commentaries
The PharmGKB: integration, aggregation, and annotation of pharmacogenomic data and knowledge
A E Hodge, R B Altman and T E Klein
Clin Pharmacol Ther 81: 21-24; doi:10.1038/sj.clpt.6100048
Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact?
R A Boyd and R L Lalonde
Clin Pharmacol Ther 81: 24-26; doi:10.1038/sj.clpt.6100058
Gene mutations, atrial fibrillation, and the elusive cigar
J F Carlquist and J L Anderson
Clin Pharmacol Ther 81: 26-28; doi:10.1038/sj.clpt.6100061
See also: Article by Chen et al.Letter to the Editor
PharmGED: Pharmacogenetic Effect Database
B Xie, C J Zheng, L Y Han, S Ong, J Cui, H L Zhang, L Jiang, X Chen and Y Z Chen
Clin Pharmacol Ther 81: 29; doi:10.1038/sj.clpt.6100008
State of the Art
State of the Art
In Silico Drug Discovery: Solving the "Target-rich and Lead-poor" Imbalance Using the Genome-to-drug-lead Paradigm
Y P Pang
Clin Pharmacol Ther 81: 30-34; doi:10.1038/sj.clpt.6100030
Research
Articles
A Common Polymorphism in SCN5A is Associated with Lone Atrial Fibrillation
L Y Chen, J D Ballew, K J Herron, R J Rodeheffer and T M Olson
Clin Pharmacol Ther 81: 35-41; doi:10.1038/sj.clpt.6100016
See also: Commentary by Carlquist & AndersonIrinotecan-induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein
F A de Jong, T J Scott-Horton, D L Kroetz, H L McLeod, L E Friberg, R H Mathijssen, J Verweij, S Marsh and A Sparreboom
Clin Pharmacol Ther 81: 42-49; doi:10.1038/sj.clpt.6100019
Mechanism-based PK/PD Modeling of the Respiratory Depressant Effect of Buprenorphine and Fentanyl in Healthy Volunteers
A Yassen, E Olofsen, R Romberg, E Sarton, L Teppema, M Danhof and A Dahan
Clin Pharmacol Ther 81: 50-58; doi:10.1038/sj.clpt.6100025
The Partial 5-Hydroxytryptamine1A Receptor Agonist Buspirone does not Antagonize Morphine-induced Respiratory Depression in Humans
B G Oertel, A Schneider, M Rohrbacher, H Schmidt, I Tegeder, G Geisslinger and J Lötsch
Clin Pharmacol Ther 81: 59-68; doi:10.1038/sj.clpt.6100018
Lopinavir/ritonavir Reduces Bupropion Plasma Concentrations in Healthy Subjects
G W Hogeland, S Swindells, J C McNabb, A D M Kashuba, G C Yee and C M Lindley
Clin Pharmacol Ther 81: 69-75; doi:10.1038/sj.clpt.6100027
Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics
N F Smith, S Marsh, T J Scott-Horton, A Hamada, S Mielke, K Mross, W D Figg, J Verweij, H L McLeod and A Sparreboom
Clin Pharmacol Ther 81: 76-82; doi:10.1038/sj.clpt.6100011
Selective AT1 Receptor Antagonism Enhances Sympathetically Mediated Vasoconstriction in Man
D Lyons, S H D Jackson and C G Swift
Clin Pharmacol Ther 81: 83-87; doi:10.1038/sj.clpt.6100023
A Bayesian Population PK–PD Model of Ispinesib-induced Myelosuppression
S J Kathman, D H Williams, J P Hodge and M Dar
Clin Pharmacol Ther 81: 88-94; doi:10.1038/sj.clpt.6100021
Frequency of CYP2D6*10 and *14 Alleles and their Influence on the Metabolic Activity of CYP2D6 in a Healthy Chinese Population
W M Cai, B Chen and W X Zhang
Clin Pharmacol Ther 81: 95-98; doi:10.1038/sj.clpt.6100015
Discovery & Development
Discovery
Aminoglycoside-induced Translational Read-through in Disease: Overcoming Nonsense Mutations by Pharmacogenetic Therapy
L V Zingman, S Park, T M Olson, A E Alekseev and A Terzic
Clin Pharmacol Ther 81: 99-103; doi:10.1038/sj.clpt.6100012
Translational Medicine
Biomarkers and Surrogate End Points for Fit-for-Purpose Development and Regulatory Evaluation of New Drugs
J A Wagner, S A Williams and C J Webster
Clin Pharmacol Ther 81: 104-107; doi:10.1038/sj.clpt.6100017
Development
Cardiac Repolarization and the Safety of New Drugs Defined by Electrocardiography
J Morganroth
Clin Pharmacol Ther 81: 108-113; doi:10.1038/sj.clpt.6100010
Regulation & Use
Practice
Two Cases of Rapid Onset Parkinson's Syndrome Following Toxic Ingestion of Ethylene Glycol and Methanol
N J Reddy, L D Lewis, T B Gardner, W Osterling, C J Eskey and D W Nierenberg
Clin Pharmacol Ther 81: 114-121; doi:10.1038/sj.clpt.6100013
Ethics
The Ethical Implications of Stratifying by Race in Pharmacogenomics
S S-J Lee
Clin Pharmacol Ther 81: 122-125; doi:10.1038/sj.clpt.6100020
Public Policies
Translational Research: Moving Discovery to Practice
E A Zerhouni
Clin Pharmacol Ther 81: 126-128; doi:10.1038/sj.clpt.6100029
Drug Development and the FDA's Critical Path Initiative
R L Woosley and J Cossman
Clin Pharmacol Ther 81: 129-133; doi:10.1038/sj.clpt.6100014
